Dare Bioscience Inc.
DARE
NSC
Sector: Healthcare
Industry: Biotechnology
1.22
USD
0.04
(3.39%)
Optionable: No Market Cap: 103 M 90-day average vol: 873,807
Previous close: 1.18 Open: 1.2 Bid: 1.23 Ask: 1.23
52 week range
0.92 2.51
Last updated: Sunday 14th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 3.43 |
PE Ratio (TTM) | -2.00 |
Book Value per Share ($) | 0.36 |
5 Year PE Range-3.2 |
Returns
7 Day Return | -2.40% | |
1 Month Return | 1.67% | |
3 Month Return | 7.96% | |
1 Year Return | -23.75% | |
3 Year Return | 52.50% | |
5 Year Return | -57.19% | |
YTD Return | -39.00% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 53.52 |
14 Day SMA ($) | 1.16 |
14 Day EMA ($) | 1.19 |
Money Flow Index | 65.20 |
Average True Range | 0.07 |
50 Day SMA ($) | 1.22 |
200 Day SMA ($) | 1.46 |
ADX | 27.36 |
MACD | 0.00 |
Growth
Free Cash Flow QoQ Growth | 24.53% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -44.44% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Daré Bioscience to Participate in Upcoming Conferences
Yahoo Finance 3/2/2022
Daré Bioscience (DARE) Investor Presentation - Slideshow
Seeking Alpha 2/17/2022
Diving Back Into Daré Bioscience Again
Seeking Alpha 1/7/2022
Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
Yahoo Finance 1/4/2022
Dare Bioscience gives back most of its strong gains from Tuesday's FDA approval
Seeking Alpha 12/10/2021
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
Yahoo Finance 12/9/2021
Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today?
Yahoo Finance 12/8/2021
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Yahoo Finance 12/8/2021
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Yahoo Finance 12/7/2021
Daré Bioscience wins FDA approval for XACIATO antibacterial gel (updated)
Seeking Alpha 12/7/2021
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Yahoo Finance 11/14/2021
Daré Bioscience, Inc. 2021 Q3 - Results - Earnings Call Presentation
Seeking Alpha 11/11/2021
Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2021 Results - Earnings Call Transcript
Seeking Alpha 11/10/2021
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Yahoo Finance 11/10/2021
Dare Bioscience EPS misses by $0.06
Seeking Alpha 11/10/2021
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
Yahoo Finance 11/10/2021
Dare Bioscience Q3 2021 Earnings Preview
Seeking Alpha 11/9/2021
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
Yahoo Finance 11/9/2021
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
Yahoo Finance 11/3/2021
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
Yahoo Finance 10/6/2021
Daré Bioscience gets NIH grant to support development of DARE-LARC1
Seeking Alpha 9/27/2021
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
Yahoo Finance 9/27/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: -0.892
Financials
DARE Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 625000 | 6000 | 80000 | 0 | 766000 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -346000 | -412000 | -126000 | -192000 | 246000 | 0 | -2440 | -11137 | -43227 | -26413 |
| Gross operating profit | 625000 | 6000 | 80000 | 0 | 766000 | 0 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 6 M | 6 M | 9 M | 11 M | 10 M | 3 M | 5 M | 6 M | 7 M | 8 M |
| Research & development expense | 16 M | 10 M | 12 M | 26 M | 28 M | 984749 | 6 M | 9 M | 21 M | 31 M |
| Operating income | -22 M | -16 M | -20 M | -37 M | -37 M | -4 M | -12 M | -14 M | -27 M | -39 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 39000 | 202000 | -2 M | -8000 | 1000 | -8 M | -5 M | 81050 | 1514 | 372407 |
| Pre-tax Income (EBT) | -22 M | -17 M | -23 M | -40 M | -39 M | -12 M | -17 M | -14 M | -27 M | -39 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -22 M | -17 M | -23 M | -40 M | -39 M | -12 M | -17 M | -14 M | -27 M | -39 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -22 M | -17 M | -23 M | -40 M | -39 M | -12 M | -17 M | -14 M | -27 M | -39 M |
| Preferred dividends | 73000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -22 M | -17 M | -23 M | -40 M | -39 M | -12 M | -17 M | -14 M | -27 M | -39 M |
| Depreciation | 346000 | 412000 | 126000 | 192000 | -246000 | 0 | 2440 | 11137 | 43227 | 26413 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -21 M | -15 M | -22 M | -37 M | -37 M | -4 M | -12 M | -14 M | -27 M | -39 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -281.76 | -20.9 | -16 | -15.6 | -14.2 | -3.56 | -1.57 | -0.97 | -0.91 | -0.63 |
| Diluted EPS total | -281.76 | -20.9 | -16 | -15.6 | -14.2 | -3.56 | -1.57 | -0.97 | -0.91 | -0.63 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!